Takeda Pharmaceutical Company Limited Message Board
-
hhh, haven't you learned to ignore stash yet, ha!
-
The question is, did they start marketing Kineret in January? Or, are they starting now Q1? Or, do we just expect them to delay like everything else? You see any CURRENT specific answers to this?
-
A dime for what? What are ya talking about? kg
- Reply to
Aug 2013 expiration of the Savient “stockholder rights plan”
by kg2931 •May 16, 2013 11:13 PMdavid, Yes, I'm talking about the same thing as the 'poison pill'. It expires this August.... kg
-
Ah, so lempe's one of those "too sexy for my Class' types, 'show me, I'm from Missouri', ha! Yes, I'm aware of the risk statements. The attorney's are the one's to determine the specifics of the "basis". Suffice we know plenty are there...
- Reply to
Aug 2013 expiration of the Savient “stockholder rights plan”
by kg2931 •May 16, 2013 11:13 PMWell, after the first day, I see Caitlyn Murphy acknowledged receiving the above email from me but no responses from her or Savient yet. I should think they are obligated to respond. kg
-
david,
I'm not familiar with a "travelzoo story" but for a 'short squeeze' to occur we need something to drive the SP back up dramatically. Until that happens, the 'short squeeze' can't begin.
I agree the CEO and other Execs keeping their lofty paychecks at this point is criminal but nothing us layman investors can do about it without legal help. I suppose shareholders can ask the Savient Board for a vote to fire specific execs, Ferrari to be the first of course.
I agree they have been keeping, "whatever is secret totally from the market and shareholders" - no doubt about it. However, all their Sec documents are in order. If you have the time to digest all of em (most don't) you will find a lot of the info that we should have been getting in the form of news releases, web site notifications, Conf Calls, etc. I guess they expect us to try to unbury these tidbits and/or read between the lines & make assumptions out of the Sec documents.
There is an element of dissengenuineness on the part of Savient; their lack of news releases, lack of notices on meetings, saying things on Conf Calls that never pan out, the list goes on. I think the executives think they have their #$%$ covered adequately and could give two sh-ts about investors. Suppose par for the course on Wall Street though - odds are worse than any Casino games....
kg -
Good man david! We just gotta hang in there. Got no other choice. kg
-
Everybody still playing 'chicken', 'politically correct' and 'too sexy for my Class Action' are we? Will try this one more time. kg
-
Thx much! kg
-
Just out of curiosity, what's the process for Savient getting a Vote on this from the shareholders? The 2013 Annual Proxy meeting agenda is already set. I would think any Sale would have to be Voted on. I'd also like to vote to renew the Shareholder Protection Plan (expiring this August!). kg
-
Knock it off you guys! We got better things to be #$%$ about here than your personal investment methods! Now you get along now - both of you - right now! kg
-
Dang good question rets! I'm not aware of any news to date from SVNT on 1st Qtr Kineret revenue. For all we know SVNT might not have even started marketing it! Guess we're supposed to wait for the June 13th Annual Shareholders Proxy Meeting and just hope that someone brings this up on the Conf Call. kg
- Reply to
Downgrade today have so far no major effect - "Market Perform with a price target of $1.00"
by kampaa_kampa •15 hours agoInvestors wait for downgrade announcements to start investing...
-
William Blair just downgraded SVNT so, Yes, I agree, it's time to buy.
-
language from pg 69, Savient Form 10-K, Annual Report, Filed Apr 1, 2013, "Funding Requirements":
"As we continue to commercialize KRYSTEXXA, we expect that our cash needs will increase, and we may need to seek additional funding through customary methods, or to explore a strategic licensing or co-promotion transaction in certain territories as a means of raising additional funding. Should we elect to seek additional funding through customary methods, we may not be able to obtain additional funds or, if such funds are available, such funding may not be on terms that are acceptable to us. If we raise additional funds by issuing equity securities, dilution to our then-existing stockholders will result. If we issue preferred stock, it would likely include a liquidation preference and other terms that would adversely affect our common stockholders. Our ability to raise additional funds through the issuance of debt securities or borrowings is limited by our current indebtedness, and any new indebtedness we may incur could become subject to substantial interest expense and financial and other covenants that could restrict our ability to take specified actions, such as incurring additional debt or making capital expenditures. If we explore a strategic licensing or co-promotion transaction, one may not be available to us or may only be available on terms that are not acceptable to us. If funds are not available on favorable terms, or at all, our business, results of operations and financial condition may be materially adversely affected and we may be required to curtail or cease operations. " -
mbuss, perhaps you're reading what I ran out of room to paste at the end of my orig msg:
"Because the immunogenicity trial may result in a different dosing schedule for KRYSTEXXA and higher response rates, we decided to push back the start of the induction/maintenance trials until the data from the immunogenicity trial is available. We believe this would allow us to conduct the induction/maintenance trials with fewer patients and at less cost, while further lessening the risk of infusion reactions for the patients. " -
Thx mbuss. I admit I'm behind on my Sec readings but now I'm confused as well. The 10K I ref'd above is from the Savient IR web site and marked "Form 10-K Annual Report Filed Apr 1, 2013" - which is later than March so I should think that "on hold" wording would be in there. Not doubting what you're telling me. I'm sure I'll find it as I review the rest of the documents. kg PS: yeah, but "$1.50 to $2.50" by when, next 3 months, next year, by when?
- Reply to
Savient is selling roughly the same amount of vials per quarter
by lempe39398 •May 15, 2013 6:08 PMlempe & mbuss,
I hope you two can come to an agreement as to whether this KPP should continue as is, be revise or discontinued. It sounds like a good think if it brings in much needed new Pts that otherwise would not come in. On the other hand, Savient is now in a do or die situation - hardly time to continue loosely giving out freebies in the hopes of customers sticking around. Two cents. kg -
You could be right and hope you are. I just finished re-reading Savient's 10K. I understand Savient has never planned to sell/commercialize K on our own anywhere outside the US. And the "Risk"s clearly state the huge challenges of trying to get by ea country's unique regulatory governing bodies. That CHMP that approved us and now this NICE rejection were just the tip of the iceberg! kg